Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.
about
Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptorRole of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potentialQuantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapyElimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.Appetite regulation and weight control: the role of gut hormones.Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.Opportunities for the replacement of animals in the study of nausea and vomitingChanges in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function.Unusual etiology of gastrointestinal symptoms: the case of jojoba butterBeneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype.Determination of gastric emptying in nonobese diabetic mice.Caloric intake capacity as measured by a standard nutrient drink test helps to predict weight loss after bariatric surgery.Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study.Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women.
P2860
Q24628602-D9213FC3-D8E1-4C4C-A3C8-572E8CAE8008Q30487910-D8ADACCF-49D8-46EF-A3AF-B8127DD6566AQ34712671-B2F86855-3FE7-4B21-B0E2-49582AF71362Q35118214-544D89DE-94E7-42B5-9AE6-0FC10E38005BQ35533535-92FEC38D-5C0B-4B6A-95CC-AEC14A1FDF74Q35825708-101FB037-174D-42DA-A8B5-FFE464DCC9C4Q36017828-FFC8CF26-156C-4490-89E3-37482FDD6DBAQ36683781-24B82206-21AB-465B-85BE-65212006F937Q37175130-77FEC4EF-D401-423A-95F2-9FB18EEC2619Q37332618-7AF4E585-323C-4C3D-8150-06D033612CA8Q38687050-08CBEAE6-823C-476E-94C3-818819445F93Q39252760-E03932F6-DCAE-4588-AEB6-3126C148E1D9Q39888037-181E5BB2-AF5E-407B-98C2-E77DAC6B4AEFQ40168206-333E5D2C-6E5D-4737-BC83-4B0AF80B9797Q46989321-21551DAE-2F52-4598-BFF5-5C0C4795BB3BQ47581433-F6FA25DB-3A52-4B70-82E1-DADD63BFC84BQ51491977-6FB83AA7-8289-4DCD-A4EB-9C2EC43C3299Q51787140-F587A1AC-80B4-4065-92C4-E84574DAD3A6
P2860
Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Effect of oral CCK-1 agonist G ...... nctions in healthy volunteers.
@en
Effect of oral CCK-1 agonist G ...... nctions in healthy volunteers.
@nl
type
label
Effect of oral CCK-1 agonist G ...... nctions in healthy volunteers.
@en
Effect of oral CCK-1 agonist G ...... nctions in healthy volunteers.
@nl
prefLabel
Effect of oral CCK-1 agonist G ...... nctions in healthy volunteers.
@en
Effect of oral CCK-1 agonist G ...... nctions in healthy volunteers.
@nl
P2093
P2860
P356
P1476
Effect of oral CCK-1 agonist G ...... nctions in healthy volunteers.
@en
P2093
Ann Walker
Anne Shachoy-Clark
Debra Stephens
Duane Burton
Emma Janet Castillo
Robin O'Connor-Semmes
Silvia Delgado-Aros
P2860
P304
P356
10.1152/AJPGI.00074.2004
P577
2004-08-01T00:00:00Z